A study of pupil dilation using the Mydriasert® ophthalmic insert;Étude de la dilatation pupillaire par l'insert ophtalmique Mydriasert®

Journal Francais d'Ophtalmologie

Volumn 27, Issue 10, 2004, Pages 1099-1108

  Levet, L ^a   Touzeau, O ^a,b,c   Scheer, S ^a   Borderie, V ^a,b   Laroche, L ^b  

^a Hôpital des XV XX   (France)

^b Hopitaux de Paris   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Dilation; Insert; Iris; Mydriasis; Pupil

Indexed keywords

EYE DROPS; MYDRIASERT; MYDRIATIC AGENT; PHENYLEPHRINE; TROPICAMIDE;

ADULT; AGED; ARTICLE; CONJUNCTIVA; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYDRIASIS; PUPIL; PUPIL DISEASE; ADOLESCENT; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; EQUIPMENT DESIGN; INSTRUMENTATION; METHODOLOGY; MIDDLE AGED; OPHTHALMOLOGY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; EQUIPMENT DESIGN; FEMALE; HUMANS; MALE; MIDDLE AGED; MYDRIATICS; OPHTHALMOLOGY; PHENYLEPHRINE; PROSPECTIVE STUDIES; PUPIL; TROPICAMIDE;

EID: 11144280481     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(04)96278-x     Document Type: Article

References (21)

1. Ducasse A. Anatomie et physiologie de l'iris. Encycl Med Chir (Elsevier, Paris) Ophtalmologie, 21-024-A-10, 2002.
2. e édition.
3. Eyeson-Annan ML, Hirst LW, Battistutta D, Green A. Comparative pupil dilatation using phenylephrine alone or in combination with tropicamide. Ophthalmology, 1998;105:726-32.
4. Levine L. Effective degree of mydriasis with phenylephrine and tropicamide. Am J Optom Physiol Opt, 1976;53:774-85.
5. Apt L, Henrick A. Pupillary dilatation with single eyedrop mydriatic. Am J Ophthalmol, 1980;89:553-9.
6. Alani SD. The ophthalmic rod: a new ophthalmic drug delivery system. Graefes Arch Clin Exp Ophthalmol 1990;228:297-301.
7. Alani SD, Hammerstein W. The ophthalmic rod - a new opthalmic drug - delivery system II. Graefes Arch Clin Exp Ophthalmol, 1990;228:302-4.
8. Aiache JM, el Meski S, Serpin G, Beyssac E. The Formulation of drug for ocular administration. Journal of biomaterials applications, 1997;11:329-48.
9. Lee YC, Millard J, Negvesky GJ, Butrus SI, Yalkowsky SH. Formulation and in vivo evaluation of ocular insert containing phenylephrine and tropicamide. Int J Pharm, 1999;182:121-6.
10. Gurtler F, Kaltsatos V, Boisrame B, Deleforge J, Gex-Fabry M, Bala LP, et al. Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive ophthalmic drug insert. Pharm Res, 1995;12:1791-5.
11. Lee VH, Li SY, Sasaki H, Saettone MF, Chetoni P. Influence of drug release rate on systemic timolol absorption from polymeric ocular inserts in the pigmented rabbit. J Ocul Pharmacol, 1994;10:421-9.
12. Aiache JM, El Meski S, Serpin G, Beyssac E, Conti R. Local tolerance and in vivo release study of a new ocular drug delivery system. DDS&S, 2001;1:85-7.
13. German EJ, Hurst MA, Wood D, Gilchrist J. A novel system for the objective classification of iris color and its correlation with response to 1% tropicamide. Ophthalmic Physiol Opt, 1998;18:103-10.
14. Touzeau O, Levet L, Borderie V, Bouchard P, Laroche L. Le segment antérieur de l'œil des diabétiques. J Fr Ophtalmol, 2004;27:859-70.
15. Huber MJ, Smith SA, Smith SE. Mydriatic drugs for diabetic patients. Br J Ophthalmol, 1985;69:425-7.
16. JS Weiss, JN Weiss, DS Greenfield. The effects of phenylephrine 2,5% versus phenylephrine 10% on pupillary dilatation in patients with diabetes. Retina, 1995;15:130-3.
17. Hammond CJ, Snieder H, Spector TD, Gilbert CE. Factors affecting pupil size after dilatation: the twin eye study. Br J Ophthalmol, 2000;84:1173-6.
18. Ghose S, Garodia VK, Sachdev MS, Kumar H, Biswas NR, Pandey R. Evaluation of potentiating effect of a drop of lignocaine on tropicamide-induced mydriasis. Invest Ophthalmol Vis Sci, 2001;42:1581-5.M
19. Di Colo G, Zambito Y. A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on polyethylene oxide. Eur J Pharm Biopharm, 2002;54:193-6.
20. Friedrih SW, Saville BA, Cheng YL, Rootman DS. Pharmacokinetic differences between ocular inserts and eyedrops. J Ocul Pharmacol Ther, 1996;12:5-18.
21. Thénot JC, Laroche L. Lacrisert: une arme dans les formes sévères de sécheresse oculaire. La revue du praticien-Médecine Générale, 1989;74:19-20.